NANJING PORT(SZ:002040) Sou Hu Cai Jing·2025-07-25 11:27Group 1 - The core viewpoint of the article highlights the successful IPO of Nanjing Weili Zhizhi Bio-Tech Co., Ltd. on the Hong Kong Stock Exchange, with a first-day opening increase of 106.86% and a closing price of 67.1 HKD per share, resulting in a total market capitalization of 13 billion HKD [1] - The company aims to raise approximately 189 million USD through this issuance, with cornerstone investors including Zhengxin Valley Capital, Gao Yi Investment, Tencent, and E Fund [1][3] - Weili Zhizhi is a clinical-stage biotech company founded in 2012, focusing on the discovery, development, and commercialization of innovative therapies, with its founders having experience in tumor immunotherapy research at the National Cancer Institute in the United States [3] Group 2 - The company has a diversified product portfolio consisting of 14 innovative drug candidates, including 4 core products, all of which are among the leading candidates in global clinical progress [4] - Despite the long R&D cycles and heavy upfront investments typical in the biopharmaceutical industry, Weili Zhizhi reported a revenue of 8.865 million CNY in 2023, with net losses of 362 million CNY, 301 million CNY, and 75.367 million CNY for the first three months of 2023, 2024, and 2025 respectively, alongside R&D expenditures of 231 million CNY, 186 million CNY, and 57.751 million CNY during the same periods [5] - The company experienced significant market interest prior to its IPO, with cumulative fundraising exceeding 1 billion CNY and a subscription multiple of 3029 times, amounting to nearly 340 billion CNY in subscription amounts [5]